This ultrasound scan will measure your mesenteric fat thickness.
Various studies have shown that mesenteric fat, may play an important role in the pathogenesis of metabolic syndrome and cardiovascular diseases (CVD).
Metabolic syndrome includes hypertension, dysglycemia, dyslipidemia, and central obesity. Adults with metabolic syndrome have an increased risk for cardiovascular diseases and diabetes.
It is now well recognized that visceral adipose tissue, notably mesenteric fat, drained by the portal circulation is metabolically more active than non-portal adipose tissues such as subcutaneous and preperitoneal fat deposits. The increased free fatty acids from these adipocytes can lead to reduced fat oxidation and ectopic fat deposition in liver and muscle, resulting in reduced glucose uptake. Furthermore, visceral adipocytes can secrete a large number of cytokines and vasoactive peptides, including interleukin-6, tumour necrosis factor α, angiotensin II, plasminogen activator inhibitor-1, etc., all of which can increase cardiovascular risks.
Mesenteric fat thickness is an independent determinant for all components of metabolic syndrome, and for every 1-mm increase in mesenteric fat thickness, the risk of metabolic syndrome was increased by 1.3-fold.
Several prospective studies have now confirmed that metabolic syndrome was associated with premature cardiovascular mortality and new onset of diabetes.